This site is intended for healthcare professionals

Speciality hub

Neurology (CNS) and Pain

Containing dedicated Learning Zones, guidelines, trials and news for related conditions in Neurology (CNS) and Pain.

Read time: 5 mins

Last updated: 11th May 2020

Welcome:

Sign in/Register

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Neurology is the branch of medicine that deals with conditions and diseases involving the central nervous system (brain and spinal cord) and the peripheral nervous systems (autonomic and somatic), including their coverings, blood vessels, and all effector tissue such as muscle.

Neurology encompasses over 5000 neurological diseases and relies on insights from fields such as neuroscience. This medical speciality deals with dementia including Alzheimer’s disease, Parkinson’s disease, neuromuscular disorders including spinal muscular atrophy and pain management as a sub-speciality.

Diseases in this section

Attention Deficit Hyperactivity Disorder (ADHD)

Containing relevant Learning Zones, guidelines, trials and news.

Dementia

Containing relevant Learning Zones, guidelines, trials and news.

Epilepsy

Containing relevant Learning Zones, guidelines, trials and news.

Neuromuscular Disorders

Containing relevant Learning Zones, guidelines, trials and news.

Pain

Containing relevant Learning Zones, guidelines, trials and news.

Parkinson's Disease

Containing relevant Learning Zones, guidelines, trials and news.

Featured Learning Zones

Learning Zone Homepage

COMT inhibition in Parkinson’s Disease

The COMT inhibition in Parkinson's Disease Learning Zone contains key information, expert opinion and interactive learning to highlight the benefit to patients of early levodopa treatment and diagnosis of the motor fluctuations which signal disease progression and prompt adjunctive treatment. Also detailing key efficacy and safety data for the approved COMT inhibitors to help inform your treatment decisions.

Learning Zone Homepage

Spinal Muscular Atrophy

SMA is caused by loss of function mutations or deletions in the SMN1 gene, which results in insufficient levels of the survival of motor neuron (SMN) protein. Find out more here.

Learning Zone Homepage

Neuroscience and Pain Learning Zone

A focus on ADHD, Alzheimer's disease, epilepsy and pain. Videos within each section, world-leading experts will help you diagnose these often challenging conditions.

Related news and insights

FDA approves Tauvid,a radioactive diagnostic agent, for PET imaging to evaluate Alzheimer's disease. Eli Lilly

Tauvid a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD).

1 mins

European Commission approves Zeposia to treat relapsing remitting multiple sclerosis.- BMS

Bristol Myers Squibb announced that the European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features. With the EC marketing authorization, Zeposia, an oral medication taken once daily, becomes the only approved sphingosine-1-phosphate (S1P) receptor modulator for RRMS patients with active disease.

1 min

Novartis announces at EAN new data for ofatumumab demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS).

Novartis announced that new ofatumumab data from the Phase III ASCLEPIOS trials and the Phase II APLIOS trial were presented virtually at the 6th Congress of the European Academy of Neurology (EAN) .

4 min

See all news

Related drugs

Solpadeine Plus Tablets

Solpadeine Plus Tablets

Solpadeine Plus Capsules

Solpadeine Plus Capsules

solpadeine max tablets

solpadeine max tablets

Paramol Tablets

Paramol Tablets

Paracodol tablets

Paracodol tablets

Paracetamol 500mg Tablets (P)

Paracetamol 500mg Tablets (P)

Paracetamol 500mg Suppositories

Paracetamol 500mg Suppositories

Paracetamol 500mg Soluble Tablets

Paracetamol 500mg Soluble Tablets

Paracetamol 500 mg Caplets

Paracetamol 500 mg Caplets

Paracetamol 250mg/5ml Oral Suspension

Paracetamol 250mg/5ml Oral Suspension

Paracetamol 250mg Suppositories

Paracetamol 250mg Suppositories

Paracetamol 250 mg/5 ml Oral Suspension PL 04917/0029)

Paracetamol 250 mg/5 ml Oral Suspension PL 04917/0029)

Paracetamol 125mg Suppositories

Paracetamol 125mg Suppositories

Paracetamol 120mg/5ml Oral Suspension

Paracetamol 120mg/5ml Oral Suspension

Related Guidelines

Cannabis-based medicinal products

This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

1 mins

Risk reduction and management of delirium

This guideline provides recommendations based on current evidence for best practice in the detection, assessment, treatment and follow up of adults with delirium, as well as reducing the risk of delirium.

1 min

Pharmacological management of migraine

This guideline provides recommendations on the pharmacological management of adults with acute migraine, and prophylaxis for patients with episodic or chronic migraine or medication overuse headache.

1 min

Read more

Your peers are looking at...

IPCRG - Meet the faculty

IPCRG - Meet the faculty

Zeposia met primary and secondary endpoints in TRUE NORTH Phase III study for adult patients with moderate to severe ulcerative colitis.- BMS

Zeposia met primary and secondary endpoints in TRUE NORTH Phase III study for adult patients with moderate to severe ulcerative colitis.- BMS

1 mins

Myovant Sciences has submitted an NDA to the FDA for its once-daily relugolix for the treatment of women with heavy menstrual bleeding associated with uterine fibroids.

Myovant Sciences has submitted an NDA to the FDA for its once-daily relugolix for the treatment of women with heavy menstrual bleeding associated with uterine fibroids.

1 mins

Phase II DESTINY-CRC01 trial of Enhertu/Enhurtu demonstrated meaningful activity in patients with HER2 positive unresectable and/or metastatic colorectal cancer.- Daiichi Sankyo + AstraZeneca

Phase II DESTINY-CRC01 trial of Enhertu/Enhurtu demonstrated meaningful activity in patients with HER2 positive unresectable and/or metastatic colorectal cancer.- Daiichi Sankyo + AstraZeneca

1 mins

Brilinta approved by FDA to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease .-AstraZeneca

Brilinta approved by FDA to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease .-AstraZeneca

1 mins

FDA approves supplemental BLA for Taltz for the treatment of active non-radiographic axial spondyloarthritis.- Eli Lilly

FDA approves supplemental BLA for Taltz for the treatment of active non-radiographic axial spondyloarthritis.- Eli Lilly

1 mins

SURE 2 phase III clinical trial of sulopenem fails to meet endpoint in complicated urinary tract infection.- Iterum Therapeutics

SURE 2 phase III clinical trial of sulopenem fails to meet endpoint in complicated urinary tract infection.- Iterum Therapeutics

1 mins

Phase II DESTINYLung01 trial positive for Enhertu/Enhurtu in HER2 mutant NSCLC.- Daiichi Sankyo and AstraZeneca.

Phase II DESTINYLung01 trial positive for Enhertu/Enhurtu in HER2 mutant NSCLC.- Daiichi Sankyo and AstraZeneca.

1 mins

BioMarin provides highlights of 4 Years of clinical data from ongoing phase 1/II study of valoctocogene roxaparvovec gene therapy for severe hemophilia A.

BioMarin provides highlights of 4 Years of clinical data from ongoing phase 1/II study of valoctocogene roxaparvovec gene therapy for severe hemophilia A.

1 mins

VBL presents positive interim data from the OVAL phase III pivotal study of VB 111 in ovarian cancer at the ASCO meeting, showing 58% or higher objective response rate

VBL presents positive interim data from the OVAL phase III pivotal study of VB 111 in ovarian cancer at the ASCO meeting, showing 58% or higher objective response rate

1 mins

Related Journals

The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinson's Disease: A Systematic Review and Meta-Analysis.

The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinson's Disease: A Systematic Review and Meta-Analysis.

1 mins

Assessing pain in non-intubated critically ill patients unable to self report: an adaptation of the Behavioral Pain Scale.

Assessing pain in non-intubated critically ill patients unable to self report: an adaptation of the Behavioral Pain Scale.

1 mins

Emergency Management of Epilepsy and Seizures.

Emergency Management of Epilepsy and Seizures.

1 mins

Executive function in eating disorders: The role of state anxiety

Executive function in eating disorders: The role of state anxiety

1 mins

Alemtuzumab depletion failure can occur in multiple sclerosis.

Alemtuzumab depletion failure can occur in multiple sclerosis.

1 mins

Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.

Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.

1 mins

Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know.

Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know.

1 mins

Association of White Matter Structure With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

Association of White Matter Structure With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

1 mins

Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.

Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.

1 mins

How do Migraines Impact Patient Day-To-Day life? An Exploratory Analysis of Patient Reported Data From The Patientslikeme Community

How do Migraines Impact Patient Day-To-Day life? An Exploratory Analysis of Patient Reported Data From The Patientslikeme Community

1 mins

Related Events

Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2020

Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2020

Alzheimer's Association International Conference (AAIC) 2020

Alzheimer's Association International Conference (AAIC) 2020

European Academy of Neurology (EAN) 2020

European Academy of Neurology (EAN) 2020

Related Clinical Trials

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

3 mins

Identification of a Biomarker Predictive of Evolution of Parkinson Disease (GLIAPARK)

Identification of a Biomarker Predictive of Evolution of Parkinson Disease (GLIAPARK)

3 mins

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

3 mins

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE3)

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE3)

4 mins

Simvastatin in Secondary Progressive Multiple Sclerosis (MS-OPT)

Simvastatin in Secondary Progressive Multiple Sclerosis (MS-OPT)

3 mins

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ?1 Month to <4 Years With Partial-onset Seizures

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ?1 Month to <4 Years With Partial-onset Seizures

3 mins

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)

1 mins

A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CLARITY)

A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CLARITY)

2 mins

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

2 mins

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS)

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS)

3 mins

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) (ENLIGHTEN)

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) (ENLIGHTEN)

3 mins

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

4 mins